Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Vertex Pharmaceuticals Inc
Revenue
Vertex Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Moderna Inc
NASDAQ:MRNA
|
Revenue
$6.8B
|
CAGR 3-Years
104%
|
CAGR 5-Years
119%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Vertex Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Vertex Pharmaceuticals Inc
Total Revenue:
9.9B
USD
|
United States:
6B
USD
|
Outside The United States:
3.8B
USD
|
Europe:
3.1B
USD
|
Other Countries Outside Of The United States ...:
719.8m
USD
|
Breakdown by Segments
Vertex Pharmaceuticals Inc
Total Revenue:
9.9B
USD
|
Product Revenues, Net:
9.9B
USD
|
Trikafta/Kaftrio:
8.9B
USD
|
Kalydeco:
475.5m
USD
|
Orkambi:
326m
USD
|
Symdeko/Symkevi:
123m
USD
|
See Also
What is Vertex Pharmaceuticals Inc's Revenue?
Revenue
9.9B
USD
Based on the financial report for Dec 31, 2023, Vertex Pharmaceuticals Inc's Revenue amounts to 9.9B USD.
What is Vertex Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
23%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Vertex Pharmaceuticals Inc have been 17% over the past three years , 26% over the past five years , and 23% over the past ten years .